[1]
Molitch ME. Diagnosis and Treatment of Pituitary Adenomas: A Review. JAMA. 2017 Feb 7:317(5):516-524. doi: 10.1001/jama.2016.19699. Epub
[PubMed PMID: 28170483]
[2]
Melmed S. Pituitary-Tumor Endocrinopathies. The New England journal of medicine. 2020 Mar 5:382(10):937-950. doi: 10.1056/NEJMra1810772. Epub
[PubMed PMID: 32130815]
[3]
Saeger W, Lüdecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. European journal of endocrinology. 2007 Feb:156(2):203-16
[PubMed PMID: 17287410]
[4]
Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, Trouillas J, Dekkers OM, European Society of Endocrinology. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. European journal of endocrinology. 2018 Jan:178(1):G1-G24. doi: 10.1530/EJE-17-0796. Epub 2017 Oct 18
[PubMed PMID: 29046323]
Level 1 (high-level) evidence
[5]
Shimon I. Metastatic Spread to the Pituitary. Neuroendocrinology. 2020:110(9-10):805-808. doi: 10.1159/000506810. Epub 2020 Feb 27
[PubMed PMID: 32101869]
[6]
Miyake Y, Adachi JI, Suzuki T, Mishima K, Araki R, Mizuno R, Nishikawa R. TERT promoter methylation is significantly associated with TERT upregulation and disease progression in pituitary adenomas. Journal of neuro-oncology. 2019 Jan:141(1):131-138. doi: 10.1007/s11060-018-03016-8. Epub 2018 Nov 3
[PubMed PMID: 30392088]
[7]
Pease M, Ling C, Mack WJ, Wang K, Zada G. The role of epigenetic modification in tumorigenesis and progression of pituitary adenomas: a systematic review of the literature. PloS one. 2013:8(12):e82619. doi: 10.1371/journal.pone.0082619. Epub 2013 Dec 18
[PubMed PMID: 24367530]
Level 1 (high-level) evidence
[8]
Stilling G, Sun Z, Zhang S, Jin L, Righi A, Kovācs G, Korbonits M, Scheithauer BW, Kovacs K, Lloyd RV. MicroRNA expression in ACTH-producing pituitary tumors: up-regulation of microRNA-122 and -493 in pituitary carcinomas. Endocrine. 2010 Aug:38(1):67-75. doi: 10.1007/s12020-010-9346-0. Epub 2010 May 27
[PubMed PMID: 20960104]
[9]
Srirangam Nadhamuni V, Korbonits M. Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms. Endocrine reviews. 2020 Dec 1:41(6):821-46. doi: 10.1210/endrev/bnaa006. Epub
[PubMed PMID: 32201880]
[10]
Bassett JH, Forbes SA, Pannett AA, Lloyd SE, Christie PT, Wooding C, Harding B, Besser GM, Edwards CR, Monson JP, Sampson J, Wass JA, Wheeler MH, Thakker RV. Characterization of mutations in patients with multiple endocrine neoplasia type 1. American journal of human genetics. 1998 Feb:62(2):232-44
[PubMed PMID: 9463336]
[11]
Crabtree JS, Scacheri PC, Ward JM, Garrett-Beal L, Emmert-Buck MR, Edgemon KA, Lorang D, Libutti SK, Chandrasekharappa SC, Marx SJ, Spiegel AM, Collins FS. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proceedings of the National Academy of Sciences of the United States of America. 2001 Jan 30:98(3):1118-23
[PubMed PMID: 11158604]
[12]
Dekkers OM, Karavitaki N, Pereira AM. The epidemiology of aggressive pituitary tumors (and its challenges). Reviews in endocrine & metabolic disorders. 2020 Jun:21(2):209-212. doi: 10.1007/s11154-020-09556-7. Epub
[PubMed PMID: 32361816]
[13]
Yoo F, Kuan EC, Heaney AP, Bergsneider M, Wang MB. Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review. Pituitary. 2018 Jun:21(3):290-301. doi: 10.1007/s11102-018-0872-8. Epub
[PubMed PMID: 29404894]
Level 2 (mid-level) evidence
[14]
Dudziak K, Honegger J, Bornemann A, Horger M, Müssig K. Pituitary carcinoma with malignant growth from first presentation and fulminant clinical course--case report and review of the literature. The Journal of clinical endocrinology and metabolism. 2011 Sep:96(9):2665-9. doi: 10.1210/jc.2011-1166. Epub 2011 Jun 29
[PubMed PMID: 21715538]
Level 3 (low-level) evidence
[15]
Santos-Pinheiro F, Penas-Prado M, Kamiya-Matsuoka C, Waguespack SG, Mahajan A, Brown PD, Shah KB, Fuller GN, McCutcheon IE. Treatment and long-term outcomes in pituitary carcinoma: a cohort study. European journal of endocrinology. 2019 Oct:181(4):397-407. doi: 10.1530/EJE-18-0795. Epub
[PubMed PMID: 31349217]
[16]
McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, Burman P, ESE survey collaborators. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. European journal of endocrinology. 2018 Mar:178(3):265-276. doi: 10.1530/EJE-17-0933. Epub 2018 Jan 12
[PubMed PMID: 29330228]
Level 3 (low-level) evidence
[17]
Kasuki L, Raverot G. Definition and diagnosis of aggressive pituitary tumors. Reviews in endocrine & metabolic disorders. 2020 Jun:21(2):203-208. doi: 10.1007/s11154-019-09531-x. Epub
[PubMed PMID: 31808044]
[18]
Alkhani AM, Cusimano M, Kovacs K, Bilbao JM, Horvath E, Singer W. Cytology of pituitary thyrotroph hyperplasia in protracted primary hypothyroidism. Pituitary. 1999 May:1(3-4):291-5
[PubMed PMID: 11081211]
[19]
Shimono T, Hatabu H, Kasagi K, Miki Y, Nishizawa S, Misaki T, Hiraga A, Konishi J. Rapid progression of pituitary hyperplasia in humans with primary hypothyroidism: demonstration with MR imaging. Radiology. 1999 Nov:213(2):383-8
[PubMed PMID: 10551216]
[20]
Mete O, Lopes MB. Overview of the 2017 WHO Classification of Pituitary Tumors. Endocrine pathology. 2017 Sep:28(3):228-243. doi: 10.1007/s12022-017-9498-z. Epub
[PubMed PMID: 28766057]
Level 3 (low-level) evidence
[21]
Trouillas J, Jaffrain-Rea ML, Vasiljevic A, Dekkers O, Popovic V, Wierinckx A, McCormack A, Petersenn S, Burman P, Raverot G, Villa C. Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician's questions. Reviews in endocrine & metabolic disorders. 2020 Jun:21(2):243-251. doi: 10.1007/s11154-020-09562-9. Epub
[PubMed PMID: 32504268]
[22]
Ebersold MJ, Quast LM, Laws ER Jr, Scheithauer B, Randall RV. Long-term results in transsphenoidal removal of nonfunctioning pituitary adenomas. Journal of neurosurgery. 1986 May:64(5):713-9
[PubMed PMID: 3701419]
[23]
Nutkiewicz A, DeFeo DR, Kohut RI, Fierstein S. Cerebrospinal fluid rhinorrhea as a presentation of pituitary adenoma. Neurosurgery. 1980 Feb:6(2):195-7
[PubMed PMID: 7366811]
[24]
Kawaguchi T, Ogawa Y, Ito K, Watanabe M, Tominaga T. Follicle-stimulating hormone-secreting pituitary adenoma manifesting as recurrent ovarian cysts in a young woman--latent risk of unidentified ovarian hyperstimulation: a case report. BMC research notes. 2013 Oct 11:6():408. doi: 10.1186/1756-0500-6-408. Epub 2013 Oct 11
[PubMed PMID: 24119690]
Level 3 (low-level) evidence
[25]
Glezer A, Bronstein MD. Pituitary apoplexy: pathophysiology, diagnosis and management. Archives of endocrinology and metabolism. 2015 Jun:59(3):259-64. doi: 10.1590/2359-3997000000047. Epub
[PubMed PMID: 26154095]
[26]
St-Jean E, Blain F, Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clinical endocrinology. 1996 Mar:44(3):305-9
[PubMed PMID: 8729527]
[27]
Ónnestam L, Berinder K, Burman P, Dahlqvist P, Engström BE, Wahlberg J, Nyström HF. National incidence and prevalence of TSH-secreting pituitary adenomas in Sweden. The Journal of clinical endocrinology and metabolism. 2013 Feb:98(2):626-35. doi: 10.1210/jc.2012-3362. Epub 2013 Jan 7
[PubMed PMID: 23295463]
[28]
Petakov MS, Damjanović SS, Nikolić-Durović MM, Dragojlović ZL, Obradović S, Gligorović MS, Simić MZ, Popović VP. Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect. Journal of endocrinological investigation. 1998 Mar:21(3):184-8
[PubMed PMID: 9591215]
[29]
Barkan AL, Chandler WF. Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the "high-dose hook effect": case report. Neurosurgery. 1998 Apr:42(4):913-5; discussion 915-6
[PubMed PMID: 9574657]
[30]
Marniemi J, Parkki MG. Radiochemical assay of glutathione S-epoxide transferase and its enhancement by phenobarbital in rat liver in vivo. Biochemical pharmacology. 1975 Sep 1:24(17):1569-72
[PubMed PMID: 9]
[31]
Asa SL, Mete O, Perry A, Osamura RY. Overview of the 2022 WHO Classification of Pituitary Tumors. Endocrine pathology. 2022 Mar:33(1):6-26. doi: 10.1007/s12022-022-09703-7. Epub 2022 Mar 15
[PubMed PMID: 35291028]
Level 3 (low-level) evidence
[32]
Verma J, McCutcheon IE, Waguespack SG, Mahajan A. Feasibility and outcome of re-irradiation in the treatment of multiply recurrent pituitary adenomas. Pituitary. 2014 Dec:17(6):539-45. doi: 10.1007/s11102-013-0541-x. Epub
[PubMed PMID: 24272035]
Level 2 (mid-level) evidence
[33]
Lasolle H, Cortet C, Castinetti F, Cloix L, Caron P, Delemer B, Desailloud R, Jublanc C, Lebrun-Frenay C, Sadoul JL, Taillandier L, Batisse-Lignier M, Bonnet F, Bourcigaux N, Bresson D, Chabre O, Chanson P, Garcia C, Haissaguerre M, Reznik Y, Borot S, Villa C, Vasiljevic A, Gaillard S, Jouanneau E, Assié G, Raverot G. Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. European journal of endocrinology. 2017 Jun:176(6):769-777. doi: 10.1530/EJE-16-0979. Epub
[PubMed PMID: 28432119]
[34]
Ji Y, Vogel RI, Lou E. Temozolomide treatment of pituitary carcinomas and atypical adenomas: systematic review of case reports. Neuro-oncology practice. 2016 Sep:3(3):188-195
[PubMed PMID: 27551432]
Level 3 (low-level) evidence
[35]
Elbelt U, Schlaffer SM, Buchfelder M, Knappe UJ, Vila G, Micko A, Deutschbein T, Unger N, Lammert A, Topuzoglu-Müller T, Bojunga J, Droste M, Johanssen S, Kolenda H, Ritzel K, Buslei R, Strasburger CJ, Petersenn S, Honegger J. Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey. The Journal of clinical endocrinology and metabolism. 2020 Mar 1:105(3):. pii: dgz211. doi: 10.1210/clinem/dgz211. Epub
[PubMed PMID: 31746334]
Level 3 (low-level) evidence
[36]
Ilie MD, Jouanneau E, Raverot G. Aggressive Pituitary Adenomas and Carcinomas. Endocrinology and metabolism clinics of North America. 2020 Sep:49(3):505-515. doi: 10.1016/j.ecl.2020.05.008. Epub 2020 Jul 8
[PubMed PMID: 32741485]
[37]
Lizzul L, Lombardi G, Barbot M, Ceccato F, Gardiman MP, Regazzo D, Bellu L, Mazza E, Losa M, Scaroni C. Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature. Pituitary. 2020 Aug:23(4):359-366. doi: 10.1007/s11102-020-01040-4. Epub
[PubMed PMID: 32232709]
[38]
Whitelaw BC. How and when to use temozolomide to treat aggressive pituitary tumours. Endocrine-related cancer. 2019 Aug:26(9):R545-R552. doi: 10.1530/ERC-19-0083. Epub
[PubMed PMID: 31311005]
[39]
Lin AL, Sum MW, DeAngelis LM. Is there a role for early chemotherapy in the management of pituitary adenomas? Neuro-oncology. 2016 Oct:18(10):1350-6. doi: 10.1093/neuonc/now059. Epub 2016 Apr 21
[PubMed PMID: 27106409]
[40]
Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T, Takano K. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. The Journal of clinical endocrinology and metabolism. 2008 Dec:93(12):4721-7. doi: 10.1210/jc.2007-2758. Epub 2008 Sep 23
[PubMed PMID: 18812485]
[41]
Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A, Endocrine Society. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism. 2015 Aug:100(8):2807-31. doi: 10.1210/jc.2015-1818. Epub 2015 Jul 29
[PubMed PMID: 26222757]
Level 1 (high-level) evidence
[42]
Raverot G, Ilie MD, Lasolle H, Amodru V, Trouillas J, Castinetti F, Brue T. Aggressive pituitary tumours and pituitary carcinomas. Nature reviews. Endocrinology. 2021 Nov:17(11):671-684. doi: 10.1038/s41574-021-00550-w. Epub 2021 Sep 7
[PubMed PMID: 34493834]
[43]
Gsponer J, De Tribolet N, Déruaz JP, Janzer R, Uské A, Mirimanoff RO, Reymond MJ, Rey F, Temler E, Gaillard RC, Gomez F. Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients. Medicine. 1999 Jul:78(4):236-69
[PubMed PMID: 10424206]
Level 2 (mid-level) evidence
[44]
Taylor SL, Barakos JA, Harsh GR 4th, Wilson CB. Magnetic resonance imaging of tuberculum sellae meningiomas: preventing preoperative misdiagnosis as pituitary macroadenoma. Neurosurgery. 1992 Oct:31(4):621-7; discussion 627
[PubMed PMID: 1407446]
[45]
Pivonello R, Colao A, Di Somma C, Facciolli G, Klain M, Faggiano A, Salvatore M, Lombardi G. Impairment of bone status in patients with central diabetes insipidus. The Journal of clinical endocrinology and metabolism. 1998 Jul:83(7):2275-80
[PubMed PMID: 9661594]
[46]
Bakhsheshian J, Wheeler S, Strickland BA, Pham MH, Rennert RC, Carmichael J, Weiss M, Zada G. Surgical Outcomes Following Repeat Transsphenoidal Surgery for Nonfunctional Pituitary Adenomas: A Retrospective Comparative Study. Operative neurosurgery (Hagerstown, Md.). 2019 Feb 1:16(2):127-135. doi: 10.1093/ons/opy078. Epub
[PubMed PMID: 29767762]
Level 2 (mid-level) evidence
[47]
Graillon T, Castinetti F, Fuentes S, Gras R, Brue T, Dufour H. Transcranial approach in giant pituitary adenomas: results and outcome in a modern series. Journal of neurosurgical sciences. 2020 Feb:64(1):25-36. doi: 10.23736/S0390-5616.16.03889-3. Epub 2017 Jan 12
[PubMed PMID: 28079350]
[48]
Guerrero-Pérez F,Vidal N,López-Vázquez M,Sánchez-Barrera R,Sánchez-Fernández JJ,Torres-Díaz A,Vilarrasa N,Villabona C, Sarcomas of the sellar region: a systematic review. Pituitary. 2021 Feb
[PubMed PMID: 32785833]
Level 1 (high-level) evidence
[49]
Wolf A, Naylor K, Tam M, Habibi A, Novotny J, Liščák R, Martinez-Moreno N, Martinez-Alvarez R, Sisterson N, Golfinos JG, Silverman J, Kano H, Sheehan J, Lunsford LD, Kondziolka D. Risk of radiation-associated intracranial malignancy after stereotactic radiosurgery: a retrospective, multicentre, cohort study. The Lancet. Oncology. 2019 Jan:20(1):159-164. doi: 10.1016/S1470-2045(18)30659-4. Epub 2018 Nov 22
[PubMed PMID: 30473468]
Level 2 (mid-level) evidence
[50]
Domingue JN, Wilson CB. Pituitary abscesses. Report of seven cases and review of the literature. Journal of neurosurgery. 1977 May:46(5):601-8
[PubMed PMID: 845649]
Level 3 (low-level) evidence
[51]
Robinson B. Intrasellar abscess after transsphenoidal pituitary adenomectomy. Neurosurgery. 1983 Jun:12(6):684-6
[PubMed PMID: 6348578]
[52]
Ciric I,Mikhael M,Stafford T,Lawson L,Garces R, Transsphenoidal microsurgery of pituitary macroadenomas with long-term follow-up results. Journal of neurosurgery. 1983 Sep
[PubMed PMID: 6886753]